[PDF][PDF] Confirmation of the high cumulati e incidence of thrombotic complications in criticall ill ICU patients ith COVID-19: an updated anal sis
H Endeman - Thrombosis Research, 2020 - scholarlypublications …
Introduction: We recently reported a high cumulative incidence of thrombotic complications
in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three …
in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three …
[HTML][HTML] Predictors of mortality and effect of drug therapies in mechanically ventilated patients with coronavirus disease 2019: A multicenter cohort study
B Lambermont, M Ernst, P Demaret… - Critical care …, 2020 - journals.lww.com
We conducted a multicenter cohort study to determine the effect of drug therapies on survival
in mechanically ventilated patients with coronavirus disease 2019. All consecutive adult …
in mechanically ventilated patients with coronavirus disease 2019. All consecutive adult …
Improved 60‐day survival but impaired general health in Swedish ICU‐COVID patients: An ambidirectional population‐based study
G Forsberg, S Berg, A Divanoglou… - Acta …, 2022 - Wiley Online Library
Background Survival among critically ill COVID‐19 patients varies between countries and
time periods. Mortality rates up to 60% have been reported in intensive care units (ICUs) …
time periods. Mortality rates up to 60% have been reported in intensive care units (ICUs) …
[HTML][HTML] Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID‐19: The Swiss COVID‐HEP randomized clinical trial
M Blondon, S Cereghetti, J Pugin, C Marti… - Research and Practice …, 2022 - Elsevier
Background Hospitalized patients with COVID‐19 suffered initially from high rates of venous
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
thromboembolism (VTE), with possible associations between therapeutic anticoagulation …
Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study
J Helms, F Severac, H Merdji, M Schenck… - Annals of intensive …, 2021 - Springer
Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …
Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
LCMG Bonfim, IS Guerini, MG Zambon, GB Pires… - Journal of Critical …, 2023 - Elsevier
Purpose The optimal amount of anticoagulation for critically ill COVID-19 patients is
controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of …
controversial. Therefore, we aimed to evaluate the efficacy and safety of escalated doses of …
Safety and efficacy of apixaban for therapeutic anticoagulation in critically ill ICU patients with severe COVID-19 respiratory disease
E Wenzler, MH Engineer, M Yaqoob, ST Benken - TH open, 2020 - thieme-connect.com
Introduction Despite the use of unfractionated heparin (UFH) or low molecular weight
heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality …
heparin (LMWH), rates of thromboembolic disease, and subsequent morbidity and mortality …
In-hospital mortality rates in SARS-CoV-2 patients treated with enoxaparin and heparin
Аbstrасt Objectives This study aimed to investigate in-hospital mortality rates in patients with
coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods This …
coronavirus disease (COVID-19) according to enoxaparin and heparin use. Methods This …
[HTML][HTML] The role of heparin in reducing in-hospital complications and three-month mortality rates in hospitalized COVID-19 patients
F Calabretta, PS Preti, M Russo, C Klersy… - European Journal of …, 2022 - ncbi.nlm.nih.gov
Many COVID-19 patients develop a coagulopathy characterized by thrombocytopenia, minor
prolongation of bleeding times and elevated serum D-dimer and fibrinogen levels, similar to …
prolongation of bleeding times and elevated serum D-dimer and fibrinogen levels, similar to …
Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: a propensity score‐matched cohort …
JP Spiegelenberg, MMHJ van Gelder… - British Journal of …, 2021 - Wiley Online Library
The hypercoagulable state observed in COVID‐19 could be responsible for morbidity and
mortality. In this retrospective study we investigated whether therapeutic anticoagulation …
mortality. In this retrospective study we investigated whether therapeutic anticoagulation …